## IQV: IQVIA Holdings Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 0.6% below STRENGTH zone (3.0-6.0%). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($218.23)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 2
- **Sentiment:** Bullish (Bullish: 0, Bearish: 0)

**1. Here's Why You Should Retain IQV Stock in Your Portfolio Now**
- Source: TradingView â€” Track All Markets | 20251229T180804 | Somewhat-Bullish | Relevance: 98%
- IQVIA (IQV) stock has outperformed its industry significantly, driven by an expected long-term EPS growth rate of 8.38% and strong collaborations with Amazon Web Services ("AWS") for AI integration in life sciences. The company shows robust revenue visibility with a growing R&DS backlog and active share repurchase programs. However, challenges include a consistently falling current ratio, indicating liquidity concerns.

**2. Marathon Asset Management Ltd Sells 40,797 Shares of IQVIA Holdings Inc. $IQV**
- Source: MarketBeat | 20251229T113232 | Somewhat-Bullish | Relevance: 95%
- Marathon Asset Management Ltd has reduced its stake in IQVIA Holdings Inc. (NYSE:IQV) by 24.1%, selling 40,797 shares to hold 128,464 shares valued at $24.4 million. Despite this sale, institutional ownership remains high at 89.62%, and analysts maintain a "Moderate Buy" rating with a consensus price target of $243.19. IQVIA also reported strong Q3 earnings, exceeding estimates and providing positive FY2025 guidance.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 1, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-02 | Morgan Stanley | $265 | $250 | +6% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-02 | Morgan Stanley | main | Overweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 5 ($1.46M) |
| Sells | 2 ($4.59M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 46.4% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 4 |

**Top Holders:**
- Vanguard Group Inc: 11.4% (-0.9%)
- Blackrock Inc.: 8.7% (+4.5%)
- Harris Associates L.: 6.7% (-3.1%)
- State Street Corpora: 4.4% (-1.0%)
- JPMORGAN CHASE & CO: 3.9% (+110.0%)

### Key Risks

1. Insider selling cluster: $4.6M in recent transactions.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 0.96 indicates undervaluation relative to growth. Analyst sentiment positive (1 raises, avg +6%). Insider selling cluster ($4.6M in 90 days), potential headwind. Institutional flow bullish (6 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $38.7B |
| Beta | 1.37 |
| 52W Range | $134.65 - $234.30 |
| Short Interest | 3.2% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.96 |
| Forward P/E | 17.6 |
| Current P/E | 19.1 |
| YoY Growth | 8.8% |
| EPS Direction | STABLE |

### Technicals

MRS_10 stable at 0.6% (minimal 5-day change). Below STRENGTH zone by 2.4pp (needs >3.0% for momentum thesis). MRS_5 at 0.8% confirms short-term momentum alignment. Full SMA alignment bullish (above 20/50/200 SMAs). RSI neutral at 58. OFD pattern: +MTL (Rally).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 0.58% (CS: 80) | Neutral |
| RSI_14 | 58.2 | Neutral |
| MACD Histogram | -0.01 | Bearish |
| vs SMA20 | 1.013x | Above |
| vs SMA50 | 1.029x | Above |
| vs SMA200 | 1.240x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $227.11
- **Stop Loss:** $218.23 (3.9% risk)
- **Target:** $235.99 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 155
- **Position Value:** $35,202.05
- **Portfolio %:** 35.20%
- **Risk Dollars:** $1,380.00
- **Risk Per Trade:** 1.38%
- **Modifiers:** L1 115% | L2 120% | Combined 1.38x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (HIGH) | 1.15x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with selective risk appetite and defensive rotation. VIX at 14.2 (2nd percentile) signals low volatility, while positive yield curve (+58bps) and stable economic indicators support continued expansion. Market breadth at 58.7% shows decent participation, but rotation into defensive names and Fed liquidity concerns warrant measured positioning.*

### Earnings

**Next:** 2026-02-05 (Est: $3.40)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $2.98 | $3.00 | +0.8% |
| 2025Q2 | $2.77 | $2.81 | +1.4% |
| 2025Q1 | $2.63 | $2.70 | +2.6% |
| 2024Q4 | $3.11 | $3.12 | +0.4% |

---
*RULE-based L3 | 2026-01-06 16:38 | MRS_10*